BIOTECH FRANCE
MEMORIES

Quick Click !			Monthly news	Home-Site				Contactexpress	Faqs	Legends	Search	Companies	Events	Environment	Memories	Home-Biotech

Hereafter is a partial list of significant Biotech companies today disappeared or not any more legally French, to witness the memory of those entrepreneurs who took the risks for a risky venture : some were acquired (and a subsidiary may still be active in France), some were merged (and their name absorbed), some were liquidated... but most entrepreneurs started again
In a Biotech world that moves swiftly memory soon holds many holes... any data additions-contributions will be highly appreciated using the CONTACTEXPRESS form
Beware, obviously, website URL and e-mails may well be outdated
Pharmaclient : Mission, Keywords Biotech, Services... MORE?

Voici une liste partielle des entreprises Biotechs importantes, aujourd'hui disparues ou bien plus du tout Françaises (légalement), éditée pour rendre hommage aux entrepreneurs qui ont pris des risques pour un projet à risques : certaines ont été acquises (et une filiale peut encore être active en France), certaines ont été fusionnées (et leur nom a été absorbé), certaines ont été liquidées... mais la plupart des entrepreneurs ont recommencé
Dans un monde des Biotechs qui bouge très vite, la mémoire tôt se remplit de nombreux trous... toutes additions-contributions pour les données, en utilisant le formulaire de CONTACTEXPRESS seront vivement appréciées
Attention, évidemment, les URL et courriels sont probablement obsolètes
Pharmaclient : Mission, Mots-clés Biotech, Services... PLUS?

ONCE FRENCH BIOTECHS, TODAY ?... HATS-OFF TO VALOROUS TEAMS !

* ADIATEC *

1998 - Bretagne
Nantes
www.adiatec.fr

Design, Diagnostics
Key words: Immunoassay kits, Ophthalmology, Allergy, Eutest, Lacrytest, Mabtest, Amplitest
Mission: to develop and manufacture rapid assays for in vivo/in vitro diagnostics of ocular allergy, babies and children allergy, and for murine monoclonal antibodies isotyping
Clients: analysis labs, research labs
info@adiatec.fr

Identity

TYPE/MANAGEMENT/INVESTORS	FINANCES/STATUS
Personal venture \| Managing Dir.-CEO: Lesser (Joël) [founder] Sc.Dir.-CSO: Fin.Dir.-CFO: BusDev: Brèche (Sébastien) Financers (Hist.): privately owned, business angels	Turnover (M€) : Total funding (M€) : n.a. Last funding (M€) : n.a. Focus : Ophthalmo Position : Clinical Company confirm : n.a.

History

DATE	MILESTONE	TYPE	TIME
2005 .12	Company liquidation	INFO	[7 years]
1998 .01	Company founded by Joël Lesser	ORGF	[0 year]

Actualisation / Updating: 12-Mai-2008

* APTANOMICS *

2001 - Rhône-Alpes
Lyon
www.aptanomics.com

Discovery, Drugs
Key words: Aptameres, Peptides, Cancer, Aptascreen, Aptaprint
Mission: to develop new treatments based on discovery of targets involved in signalling pathways that are deregulated in a broad range of cancers
Clients: Pharmaceutical industry (own development up to preclinical stage)
info@aptanomics.com

Identity

TYPE/MANAGEMENT/INVESTORS	FINANCES/STATUS
Spin-off \| Managing Dir.-CEO: Chatelier (Jean) Sc.Dir.-CSO: Fin.Dir.-CFO: BusDev: Financers (Hist.): AGF P.E., CDC Ixis, Ventech, Biogestion	Turnover (M€) : 0.05 (2006) Total funding (M€) : 7.0 Last funding (M€) : 7.0 Focus : Cancers Position : Preclin Company confirm : n.a.

History

DATE	MILESTONE	TYPE	TIME
2007 .07	Financial complete burn-out and bankruptcy	INFO	[6 years]
2006 .11	Divestiture of some R&D assets to Imaxio (UK)	LICOUT	[5 years]
2005 .06	Partnering research agreement with Boehringer-Ingelheim in aptamer-based target validation	R&D	[4 years]
2003 .05	Nomination : Michael Courtney [ex-Transgene], as CEO	ORGN	[2 years]
2002 .11	1st round-financing : 7 M€, by AGF P.E., CDC Ixis, Ventech	RFINA	[1 year]
2001 .03	Company founded by John Hawken, Pierre Colas [Inserm, CSO], as a spin-off from Normale Sup (Lyon), based on patents from Massachusetts General Hospital	ORGF	[0 year]

Actualisation / Updating: 12-Mai-2008

* BIONEXIS PHARMACEUTICALS *

2002 - IDF
Paris
www.bionexis.com

Discovery, Drugs
Key words: Imaging radio-pharmaceuticals, Targeted drugs, Lipid-protein interaction, Apoptosis, Afim
Mission: to develop intelligent molecules for imaging and therapeutic applications, based on know-how on membrane protein-lipid interactions, focused on pathological apoptosis
Clients: Prescribers
info@bionexis.com

Identity

TYPE/MANAGEMENT/INVESTORS	FINANCES/STATUS
Personal venture \| Managing Dir.-CEO: Rodgers (Brid) [Ph.D. molecular biology, MBA, ex-Monitor] Sc.Dir.-CSO: Russo-Marie (Françoise) [co-founder, ex-Inserm] & Samson (Alain) [co-founder, University Professor] Fin.Dir.-CFO: BusDev: Financers (Hist.): Edmond de Rotschild I.P., Bioam, Sophia Euro lab, FCJE (CDC), CEA	Turnover (M€) : Total funding (M€) : 6.0 Last funding (M€) : 6.0 Focus : Cancers Position : Incubator Company confirm : n.a.

History

DATE	MILESTONE	TYPE	TIME
2004 .12	Company liquidation	INFO	[2 years]
2004 .02	1st round-financing : 6 M€, led by Edmond de Rotschild I.P., with Bioam, Sophia Euro lab, FCJE (CDC), CEA	RFINA	[2 years]
2004 .02	Company move from Saclay (CEA) to Paris (Biotech)	RELOC	[2 years]
2002 .02	Company founded by Françoise Russo-Marie and Alain Samson	ORGF	[0 year]

Actualisation / Updating: 12-Mai-2008

* BIONISIS *

1999 - IDF
Le Plessis (near Paris)
www.bionisis.com

Contract, Research
Key words: High-throughput, Purification, OPLC technology (Optimum Performance Laminar Chromatography), Sorbent beds
Mission: to provide third parties with proprietary solutions for the separation, purification and analysis of chemical and biochemical mixtures resulting from organic synthesis, natural product extraction and biological fluids
Clients: Pharmaceutical industry, Research labs
webmaster@bionisis.com

Identity

TYPE/MANAGEMENT/INVESTORS	FINANCES/STATUS
Personal venture \| Managing Dir.-CEO: Manach (Michel) Sc.Dir.-CSO: Fin.Dir.-CFO: BusDev: Financers (Hist.): Sofimac, Ventech, Siparex, OTC A.M.	Turnover (M€) : 0.5 (2004) Total funding (M€) : n.a. Last funding (M€) : n.a. Focus : Multiple Position : Subcontractor Company confirm : n.a.

History

DATE	MILESTONE	TYPE	TIME
2008 .03	Company liquidation	INFO	[8 years]
2002 .09	2nd round-financing : 2.5 M€	RFINB	[2 years]
1999 .10	Company founded by unknown entrepreneurs	ORGF	[0 year]

Actualisation / Updating: 12-Mai-2008

* CAREX *

2001 - Alsace
Strasbourg
www.carex.fr

Discovery, Drugs
Key words: Diabetes
Mission: to undertake innovative research of metabolic diseases, such as type 2 diabetes, obesity and dyslipidemia
Clients: Pharmaceutical industry
carex@carex.fr

Identity

TYPE/MANAGEMENT/INVESTORS	FINANCES/STATUS
Start-up \| Managing Dir.-CEO: Race (Geoffrey) [ex-Adprotech] Sc.Dir.-CSO: Fin.Dir.-CFO: Margetson (Shelley) BusDev: Financers (Hist.): Sofinnova Partners, GIMV, Mara Ventures (USA), Crédit Lyonnais P.E., Global Life Science Ventures, BioMedinvest, HBM	Turnover (M€) : Total funding (M€) : 31.0 Last funding (M€) : 25.0 Focus : Metabolism Position : Preclin Company confirm : n.a.

History

DATE	MILESTONE	TYPE	TIME
2006 .05	Acquisition by 7TM Pharma (Denmark)	ACQ-	[5 years]
2004 .03	2nd round-financing : 25 M€, by Crédit Lyonnais P.E., Global Life Science Ventures, BioMedinvest, HBM, and previous shareholders	RFINB	[3 years]
2002 .07	Nomination : Geoffrey Race, as CEO		[1 year]
2002 .04	1st round-financing : 6 M€, led by Sofinnova Partners, GIMV and Mara Ventures	RFINA	[1 year]
2001 .11	Company founded by Johan Auwerx, Pierre Chambon, Samir S. Deeb, Hana Koutnikova, Jürgen M.Lehmann, based on research from Institut de Génétique et de Biologie Moléculaire et Cellulaire, by Pierre Chambon (President of the board)	ORGF	[0 year]

Actualisation / Updating: 12-Mai-2008

* CELOGOS *

2001 - IDF
Paris
www.celogos.fr

Discovery, Drugs
Key words: Muscle regeneration, Cell repair, Technology platform, Rational Cell Design (RCD), Stress urinary incontinence, Anal incontinence, Ocular myopathies
Mission: to develop and produce innovative cell-based technologies in the field of cellular medicine
Clients: Pharmaceutical industry
contact@celogos.fr

Identity

TYPE/MANAGEMENT/INVESTORS	FINANCES/STATUS
Personal venture \| Managing Dir.-CEO: Ulmann (André) [M.D., Ph.D. endocrinology, ex-Hoechst, Roussel Uclaf] Sc.Dir.-CSO: Pinset (Christian) [founder, M.D., ex-CNRS, Institut Pasteur] Fin.Dir.-CFO: BusDev: Financers (Hist.): privately owned	Turnover (M€) : Total funding (M€) : 3.0 Last funding (M€) : n.a. Focus : Muscle Position : Preclin Company confirm : n.a.

History

DATE	MILESTONE	TYPE	TIME
2006 .01	Acquisition by HRA Pharma of majority share, with Celogos maintained as a French subsidiary and Christian Pinset as CSO	ACQ-	[4 years]
2005 .11	Partnering research agreement, HRA Pharma, for pharmaceutical development process of future lead compounds	R&D	[4 years]
2001 .08	Company founded by Christian Pinset, cell therapy expert and Didier Montarras (from Institut Pasteur, in Paris)	ORGF	[0 year]

Actualisation / Updating: 12-Mai-2008

* CELLPEP *

1998 - IDF
Paris
www.cellpep.fr

Delivery, Drugs
Key words: Generics, Value-added, Long acting release, Formulation, Octreotide, Goserelin
Mission: to develop therapeutics in oncology and infectious diseases
Clients: Pharmaceutical industry
jpboulan@cellpep.fr

Identity

TYPE/MANAGEMENT/INVESTORS	FINANCES/STATUS
Start-up \| Managing Dir.-CEO: de Rougé (Bonabes) [co-founder, M.D., ex-Servier, Beaufour-Ipsen] Sc.Dir.-CSO: Mollard (Michel) [co-founder, also Seventure, ex-Beaufour-Ipsen, Cooper] Fin.Dir.-CFO: BusDev: Financers (Hist.): Seventure	Turnover (M€) : Total funding (M€) : n.a. Last funding (M€) : n.a. Focus : Multiple Position : Clinical Company confirm : n.a.

History

DATE	MILESTONE	TYPE	TIME
2006 .03	Acquisition by Procyon (Canada), for 39 MUS$, to form a new legal entity, Ambrilia Biopharma (www.ambrilia.com)	ACQ-	[8 years]
2003 .03	Round-financing : 3.8 M€, by Turenne Capital Partenaires, OTC Asset Management, H2i Management, Synergènes	RFIN	[5 years]
1998 .00	Company founded by Bonabes de Rougé, Michel Mollard and others	ORGF	[0 year]

Actualisation / Updating: 12-Mai-2008

* DIATOS *

1999 - IDF
Paris
www.diatos.com

Delivery, Drugs
Key words: Drug delivery, Peptides, Tumor targeting, Cancer, Chemotherapy, Prodrugs, Liposome, Vectocell, DaunoXome
Mission: to research, develop and market targeted anti-cancer drugs based on drug-delivery improvements
Clients: Prescribers
contact@diatos.com

Identity

TYPE/MANAGEMENT/INVESTORS

FINANCES/STATUS

Spin-off |
Managing Dir.-CEO: Tchélingérian (John) [born 1965, Ph.D. neuroscience, ex-Neurotech (co-founder), Key Obs (co-founder)]
Sc.Dir.-CSO: Gasmi (Jamal) [M.D. Oncology, Ms. Sciences, ex-Roche, Gustave Roussy]
Fin.Dir.-CFO:
SalesMktg: Cowburn (James) [Ph.D. Biochemistry, ex-Zeneus Pharma, Roche, Schering Plough]
BusDev:
Financers (Hist.): GIMV, InterWest Partners, Société Générale A.M., AGF P.E., Sopartec, Sofinnova Partners, NIF, Crédit Lyonnais P.E. (today Crédit Agricole P.E.), Innoven, BFF, Credit Agricole P.E.

Turnover (M€) : 0.49 (2007), 0.30 (2006)
Total funding (M€) : 54.8
Last funding (M€) : 9.4
Focus : Cancers
Position : Trade
Company confirm : none

History

DATE	MILESTONE	TYPE	TIME
2009 .05	Company bankruptcy (in need of € 10 Million re-financing), then liquidation	INFO	[10 years]
2008 .12	Licensing-out of DTS-108, a pro-drug of irinotecan to Drais (with co-development)	LICOUT	[9 years]
2008 .08	Clinical trial (phase IIa) for DTS-201, a peptidic prodrug of doxorubicin (beginning)	CLIN	[9 years]
2007 .07	4th round-financing : 9.4 M€, by Credit Agricole P.E. and previous shareholders	RFIND	[8 years]
2006 .07	Listing : failure of IPO introduction on Alternext, cancelled due to unfavorable market conditions	PBO	[7 years]
2006 .05	Licensing-in of specialty cancer product from Gilead	LICIN	[7 years]
2005 .04	Set-up of US subsidiary in California, USA (Business)	ORGC	[6 years]
2004 .03	Set-up of subsidiary in Leuven, Belgium (R&D)	ORGC	[5 years]
2004 .02	3rd round-financing : 7.0 M€, by Innoven and BFF (Biotech Fund Flanders)	RFINC	[5 years]
2003 .05	2nd round-financing : 9.0 M€, by NIF and Crédit Lyonnais P.E. (today Crédit Agricole P.E.)	RFINB	[4 years]
2003 .04	Licensing-out of cancer improved-delivery drug development to Medarex	LICOUT	[4 years]
2000 .10	1st round-financing : 15.5 M€, led by GIMV and InterWest Partners, with Société Générale A.M., AGF P.E., Sopartec, Sofinnova Partners	RFINA	[1 year]
1999 .05	Seed financing : 1.5 M€, by Sofinnova Partners (subsequently John Tchélingérian joins the company as business developper)	SFIN	[0 year]
1999 .02	Company founded by Prof. Stratis Avraméas, Dr Thérèse Ternynck, as a spin-off from Institut Pasteur	ORGF	[0 year]

Actualisation / Updating: 18-Mai-2009

* DRUGABUSE SCIENCES *

1997 - Rhône-Alpes
Villeurbanne
(near Lyon)
www.drugabusesciences.com

Discovery, Drugs
(also, Delivery, Drugs)
Key words: Antagonism, Addiction, Alcoholism, Toxicomany, Cocaine, Opioids, Naltrexone Depot
Mission: to discover, develop and market medications for the treatment of alcohol and substance abuse and dependence
Clients: Prescribers
mdupire@drugabusesciences.com

Identity

TYPE/MANAGEMENT/INVESTORS

FINANCES/STATUS

Start-up |
Managing Dir.-CEO: Langlois (Patrick) [born 1945, ex-Aventis (Board member, Rhône Poulenc]
Sc.Dir.-CSO:
Fin.Dir.-CFO:
BusDev:
Financers (Hist.): CDC Ixis, Canaan Partners, Bionex, Jalla Equities, Palldin Group, 3i, ABN Amro, Ace Management
Note : company initially founded in USA (Hayward, California) in December 1994, with an additional base in Paris in December 1997, then legally moved to France in 2004 (through a reversed merger)

Turnover (M€) : n.a.
Total funding (M€) : n.a.
Last funding (M€) : n.a.
Focus : Addiction
Position : Clinical
Company confirm : n.a.

History

DATE	MILESTONE	TYPE	TIME
2008 .05	Company liquidation : legal dissolution	INFO	[10 years]
2007 .01	Divestiture of assets (product portfolio, including naltrexone) to Elbion (Belgium) for undisclosed terms	ACQ-	[9 years]
2006 .06	Listing on Alternext processed : 20 M€ expected (failed)	PBO	[8 years]
2004 .01	Acquisition of mother US company by French subsidiary, with new CEO (Robert Floch) and 4.0 M€ convertible loan by CDC Ixis	ACQ+	[6 years]
2001 .04	Round-financing : 27.0 M€, by Canaan Partners, Bionex, Jalla Equities, Palldin Group, 3i, ABN Amro, Ace Management	RFIN	[3 years]
1999 .10	Round-financing : 21.0 M€, by 3i, ABN Amro, Auriga, CDC Innovation, Financière de Brienne, Nomura, Parnib, Partech, Rothschild Asset Management, Société Générale A.M.	RFIN	[1 year]
1997 .12	Company founded by Philippe Pouletty (today Truffle Ventures), with name also shortened as DAS	ORGF	[0 year]

Actualisation / Updating: 12-Mai-2008

* ENDOCELLS *

2004 - IDF
Paris
www.no-website.net

Design, Therapy
Key words: Cell therapy, Transplantation, Type 1 Diabetis, Insulin
Mission: to generating lines of human pancreatic beta cells immortalized in culture for transplantation therapies
Clients: Research labs
dslagel@esperanteventures.com

Identity

TYPE/MANAGEMENT/INVESTORS	FINANCES/STATUS
Personal venture \| Managing Dir.-CEO: Slagel (Dean) [born 1970] Sc.Dir.-CSO: Fin.Dir.-CFO: BusDev: Financers (Hist.):	Turnover (M€) : Total funding (M€) : n.a. Last funding (M€) : n.a. Focus : Diabetes Position : Incub Company confirm : n.a.

History

DATE	MILESTONE	TYPE	TIME
2008 .05	Acquisition by Esperante Ventures (Holland)	ACQ-	[3 years]
2004 .08	Company founded by Prof. Paul Czernichow [M.D. pediatry], Raphaël Scharfmann [Inserm]	ORGF	[0 year]

Actualisation / Updating: 24-Sep-2008

* FOVEA PHARMACEUTICALS *

2005 - IDF
Paris
www.fovea-pharma.com

Discovery, Drugs
Key words: Ophthalmology, Allergy conjunctivitis, Mavular edema, Retinitis pigmentosa
Mission: to discover and develop new treatments focused on ocular diseases (dry eye, age-related macular degeneration, retinitis pigmentosa, diabetic retinopathy), with a special focus on retinal pathologies
Clients: Pharmaceutical industry (own development, up to preclinical)
info@fovea-pharma.com

Age: . AGE() . year(s)

Identity

TYPE/MANAGEMENT/INVESTORS

FINANCES/STATUS

Start-up |
Managing Dir.-CEO: Gilly (Bernard) [born 1957, Ph.D. bioeconomy, ex-Sofinnova, Transgene (CEO), Pasteur-Mérieux-Connaught]
Sc.Dir.-CSO:
Fin.Dir.-CFO: Davitian (Bernard) [born 1960, MBA, ex-Neurotech (CEO), Transgene, Pasteur-Mérieux]
Oper.Dir.: Bélichard (Pierre) [ex-Urogene, Ethypharm, Fournier]
BusDev: Sternberg (Garry) [M.D., MBA, ex-Eyetech, BMS]
Financers (Hist.): Sofinnova Partners, CAPE, Abingsworth Mangement, The Wellcome Trust, GIMV

Turnover (M€) : 0.04 (2007), 0.005 (2006)
Total funding (M€) : 50.5
Last funding (M€) : 30.0
Focus : Ophthalmo
Position : Preclin
Company confirm : neutral

History

DATE	MILESTONE	TYPE	TIME
2009 .10	Acquisition by Sanofi Aventis (France), for 370 M€	ACQ-	[4 years]
2009 .05	Clinical trial (proof-of-concept, positive) for Prednisporin (FOV1101) in patients with persistent allergic conjunctivitis	CLIN	[4 years]
2009 .02	Licensing-in of European rights of an ocular formulation of DX-88 for the treatment of retinal diseases from Dyax	LICIN	[3 years]
2007 .12	2nd round-financing : 30.0 M€, by previous shareholders	RFINB	[2 years]
2007 .11	Partnering research agreement with Genzyme	R&D	[2 years]
2005 .11	1st round-financing : 20.5 M€, by Sofinnova Partners, CAPE, Abingsworth Management, The Wellcome Trust, GIMV	RFINA	[0 year]
2005 .05	Company founded by Bernard Gilly, Pierre Bélichard, Prof. José-Alain Sahel (professor, Ophthalmology), based on platform from INSERM research unit 592	ORGF	[0 year]

Actualisation / Updating: 05-Oct-2009

* GÉNOPOÏETIC *

1993 - Rhône-Alpes
Miribel (Ain)
www.genopoietic.fr

Discovery, Drugs
Key words: Autologous vaccine
Mission: to develop autologous chondrocytes for cartilage repair, gene therapy to treat cancer, as well as to treat graft-versus-host disease (innovative anticancer drugs)
Clients: Pharmaceutical industry
info@genopoietic.fr

Identity

TYPE/MANAGEMENT/INVESTORS	FINANCES/STATUS
Star-up \| Managing Dir.-CEO: Fourthin (Isabelle) [M.D., MBA Essec, ex-MSD, Osteotech] Sc.Dir.-CSO: Fourthin (Isabelle) Fin.Dir.-CFO: BusDev: Financers (Hist.): Rhône-Poulenc Rorer (Gencells), then Avax (listed on US Stock Exchange)	Turnover (M€) : n.a. Total funding (M€) : n.a. Last funding (M€) : n.a. Focus : Cancers Position : Clinical Company confirm : n.a.

History

DATE	MILESTONE	TYPE	TIME
2008 .11	Nomination : François R. Martelet (Avax CEO since 2007) as President, and Isabelle Fourthin as Managing Director	ORGN	[14 years]
2000 .08	Acquisition by Avax Technologies, Philadelphia (USA)	ACQ-	[6 years]
1994 .11	Round-financing : undisclosed M€, by Rhône-Poulenc Rorer (France), against a minority share to support gene therapy trials	RFIN	[0 year]
1993 .12	Company founded by David Klatzmann and Jean-Loup Salzmann with the support of UPMC (Université Pierre et Marie Curie), with Charles Salzmann as CEO	ORGF	[0 year]

Actualisation / Updating: 12-Mai-2008

* GENSET *

1989 - IDF
Paris
www.genset.fr

Discovery, Drugs
Key words: Pharmacogenomics, DNA sequences
Mission: to undertake research programs in the field of genomics, to analyze the regulatory sequences of the human genome and to initiate the construction of a map of single nucleotide polymorphisms as a tool to accelerate the discovery of genes associated with diseases, notably for CNS and metabolism
Clients: Pharmaceutical industry, Research labs
contacts@genset.fr

Identity

TYPE/MANAGEMENT/INVESTORS	FINANCES/STATUS
Start-up \| Managing Dir.-CEO: Pernet (André) Sc.Dir.-CSO: Vassuer (Marc) [co-founder, Ph.D.] Pharm.Dir.: Ravel (Denis) [Ph.D.] Fin.Dir.-CFO: BusDev: Financers (Hist.): J.P. Morgan, Public Note : in 1999, Genset reported identifiable assets of 80.9 Million € and had subsidiaries in USA, Japan, Singapore, and Australia	Turnover (M€) : Total funding (M€) : n.a. Last funding (M€) : n.a. Focus : Multiple Position : Incub Company confirm : n.a.

History

DATE	MILESTONE	TYPE	TIME
2002 .06	Acquisition by Serono (Switzerland) [today Merck-Serono]	ACQ-	[13 years]
1996 .06	Listing on Nasdaq : 100 MUS$ (about 80 M€)	PBO	[7 years]
1989 .00	Company founded by Marc Vasseur (a leading French scientist), Pascal Brandys (CEO, venture capitalist)	ORGF	[0 year]

Actualisation / Updating: 12-Mai-2008

* HEMOSYSTEM *

1999 - Méditerranée
Marseille
www.hemosystem.com

Discovery, Diagnostics
Key words: Bacteria, Micro-array, ScanSystem
Mission: to develop new diagnostic tools and associated devices to improve safety in blodd transfusion medecine
Clients: Blood transfusion centers, Hospitals
info@hemosystem.com

Identity

TYPE/MANAGEMENT/INVESTORS	FINANCES/STATUS
Personal venture \| Managing Dir.-CEO: Hermet (Jean-Pierre) [founder, MBA, ex-Bentley Pharma, American Home Products, Allergan] Sc.Dir.-CSO: Besson-Faure (Isabelle) [Pharm.D., ex-Stago] Fin.Dir.-CFO: Allione (Monique) [Sup de Co (Marseille), DESCF, ex-Quater Oats, Irex (Synthelabo)] BusDev: Financers (Hist.): Société Générale A. M., XAnge, Avenir Finance Gestion, FJCE (CDC)	Turnover (M€) : 0.7 (2004) Total funding (M€) : 5.3 Last funding (M€) : 3.0 Focus : Hematology Position : Trade Company confirm : n.a.

History

DATE	MILESTONE	TYPE	TIME
2006 .10	Company liquidation	INFO	[7 years]
2004 .09	Round-financing : 3.0 M€, by FCJE (CDC), and previous shareholders	RFIN	[5 years]
1999 .05	Company founded by Jean-Pierre Hermet (CEO)	ORGF	[0 year]

Actualisation / Updating: 12-Mai-2008

* IDM PHARMA *

1987 - IDF
Paris
www.idm-biotech.com

Discovery, Drugs
Key words: Melanoma, Sarcoma, Infectious diseases, Junovan
Mission: to develop innovative products that activate the immune system to treat cancers
Clients: Prescribers
idm@idm-biotech.com

Identity

TYPE/MANAGEMENT/INVESTORS	FINANCES/STATUS
Start-up \| Managing Dir.-CEO: Romet-Lemonne (Jean-Loup) [co-founder] Sc.Dir.-CSO: Fin.Dir.-CFO: BusDev: Financers (Hist.):	Turnover (M€) : Total funding (M€) : n.a. Last funding (M€) : n.a. Focus : Cancers Position : Clinical Company confirm : n.a.

History

DATE	MILESTONE	TYPE	TIME
2009 .05	Acquisition by Takeda, for US$ 75 Million	ACQ-	[22 years]
2008 .02	Partnering research agreement ended with Sanofi-Aventis, after disappointing results on Junovan	R&D	[21 years]
2007 .06	Nomination : Timothy Walbert, new CEO and Chairman, with resignation by founder Jean-Loup Romet-Lemonne	ORGN	[20 years]
2005 .03	Acquisition by Epimune, as a merger with name change from IDM to IDM-Pharma	ACQ-	[18 years]
2002 .12	Round-financing : 20.0 M€, by Sanofi-Synthelabo (exclusive, shareholding : 11%)	RFIN	[15 years]
2002 .01	Partnering research agreement with Sanofi-Synthelabo	R&D	[15 years]
2000 .11	Round-financing: 48.9 M€	RFIN	[13 years]
1993 .12	Company founded by Jean-Loup Romet-Lemonne (as Immuno-Designed Molecules, IDM)	ORGF	[6 years]

Actualisation / Updating: 05-Jun-2009

* IVAGEN *

2002 - Méditerranée
Bernis
(near Nîmes)
www.ivagen.com

Discovery, Diagnostics
Key words: Immuno-hematology, Medical devices, HIV, H5N1
Mission: to develop, manufacture and distribute reagents to assist third parties in human, veterinary and plant diagnosis, and to discover proprietary immuno-diagnostics
Clients: Research labs
contact@ivagen.com

Identity

TYPE/MANAGEMENT/INVESTORS	FINANCES/STATUS
Personal venture \| Managing Dir.-CEO: Skorski (Gilbert) [born 1955] Sc.Dir.-CSO: Da Costa (Jean-Manuel) Fin.Dir.-CFO: BusDev: Financers (Hist.): Matignon I.G., OTC Asset Management (33%) Communication: website under construction, since long	Turnover (M€) : 1.05 (2006) Total funding (M€) : n.a. Last funding (M€) : n.a. Focus : Virus Position : Trade Company confirm : none

History

DATE	MILESTONE	TYPE	TIME
2008 .07	Company liquidation	INFO	[6 years]
2007 .04	Round-financing : undisclosed M€, by Matignon I.G., OTC Asset Management (after receivership in 2004)	RFIN	[5 years]
2002 .02	Company founded by Jean-Claude Aziza (unexpectedly deceased in 2006), Gilbert Skorski	ORGF	[0 year]

Actualisation / Updating: 31-Oct-2008

* MERISTEM THERAPEUTICS *

1998 - Centre
Clermont-Ferrand
www.meristem-therapeutics.com

Design, Drugs
(also Discovery, Drugs)
Key words: Therapeutic Proteins, Gene technology, Plants, MABs, Manufacturing, Processing, Third Parties, Merispase, Cystic fibrosis
Mission: to produce therapeutic proteins (e.g., monoclonal antibodies) for third parties needs, with many advantages in comparison to other systems (biological safety, high flexibility, low cost), and to develop own portfolio of innovative therapeutic proteins
Clients: Pharmaceutical industry, Biotechs
meristem@meristem-therapeutics.com

Identity

TYPE/MANAGEMENT/INVESTORS

FINANCES/STATUS

Start-up |
Managing Dir.-CEO: Rohmer (Jean-Paul) [born 1947, Ph.D. Management, Dauphine, ex-Eli Lilly, Stallergènes (CEO)]
Sc.Dir.-CSO: Burtin (Daniel) [Ph.D. Biochemistry, ex-INRA]
Oper.Dir.: Boisgard (Catherine) [ex-Human Resources]
Fin.Dir.-CFO:
BusDev:
Financers (Hist.): Limagrain (Unigrains), BNP, Tethys, 3i, Sofipar, Sofimac, AGF P.E., Antin Innovation, CPR P.E., Innoven, Edmond de Rotschild I.P., Odyssée Ventures, Pechel Industrie, SPEF

Turnover (M€) : 0.17 (2006)
Total funding (M€) : 60.0
Last funding (M€) : n.a.
Focus : Multiple
Position : Trade
Company confirm : none

History

DATE	MILESTONE	TYPE	TIME
2008 .08	Company liquidation	INFO	[10 years]
2007 .10	Court : applications on appeal for GMO corn testing, rejected by tribunal	LEGAL	[9 years]
2004 .02	Nomination : Jean-Paul Rohmer, chairman of Supervisory Board	ORGN	[5 years]
2002 .06	4th round-financing : 21.5 M€, by AGF P.E., Antin Innovation, CPR P.E., Innoven, Edmond de Rotschild I.P., Odyssée Ventures, Pechel Industrie, SPEF, and previous shareholders	RFIND	[4 years]
2001 .07	Listing : failure of IPO introduction due to unfavorable financial environment for 54 M€ expected	PBO	[3 years]
2000 .11	Acquisition of Sedaherb, phyto-subcontractor to pharmaceutical industry, for around 1 year turnover, 3.5 M€	ACQ+	[2 years]
2000 .06	3rd round-financing : 10.0 M€, by BNP, Tethys, 3i, Sofipar, Sofimac	RFINC	[2 years]
1999 .02	2nd round-financing : 18.3 M€, by Banexi Ventures 2, Banexi, 3i, Sofimac (Société de Financement du Massif Central), Sofipar (groupe Crédit Agricole) and capital disposal by Limagrain to the financial investors	RFINB	[0 year]
1998 .05	1st round-financing : 10.0 M€, by Limagrain	RFINA	[0 year]
1998 .04	Company founded by Limagrain (Agro-food cooperative company, the number one seed producer in Europe), based on an innovative technology (Molecular Pharming) developped since 1992	ORGF	[0 year]

Actualisation / Updating: 16-Feb-2009

* NAUTILUS BIOTECH *

2000 - IDF
Évry
(near Paris)
www.nautilusbiotech.com

Delivery, Drugs
Key words: Therapeutic Proteins, Slow-released HGH, Interferon alpha, Vitatropin, Belerofon
Mission: to develop therapeutic proteins with novel and superior pharmacological profiles compared with established best-in-class protein drugs
Clients: Prescribers
contact@nautilusbiotech.com

Identity

TYPE/MANAGEMENT/INVESTORS	FINANCES/STATUS
Start-up \| Managing Dir.-CEO: Parkinson (Philip) [born 1956, MBA, ex-Pfizer France] Sc.Dir.-CSO: Drittanti (Lila) [ex-Genethon] Fin.Dir.-CFO: BusDev: Vega (Manuel) [co-founder, born 1960, Ph.D., ex-Microgen, Genethon] Financers (Hist.): Auriga Partners, Matignon Tech, Edmond de Rothschild I.P., FCJE (CDC), 123 Ventures, Creabilis Therap.	Turnover (M€) : 0.38 (2006) Total funding (M€) : 25.3 Last funding (M€) : 8.4 Focus : Multiple Position : Prereg Company confirm : none

History

DATE	MILESTONE	TYPE	TIME
2008 .11	Company liquidation	INFO	[8 years]
2007 .04	Clinical trial (phase I) for Belerofon in USA (beginning)	CLIN	[7 years]
2007 .04	4th round-financing : 8.4 M€, by Pre-IPO Invest, Auriga Partners, Matignon Tech, Edmond de Rothschild I.P., FCJE (CDC), 123 Ventures, Creabilis Therap.	RFIND	[7 years]
2007 .02	Partnering research agreement with Wyeth on hemophilia therapies	R&D	[7 years]
2005 .02	3rd round-financing : 7.25 M€, by Auriga Partners, Matignon Tech, Edmond de Rothschild I.P., FCJE (CDC), 123 Ventures, Creabilis Therap.	RFINC	[5 years]
2005 .02	Nomination : Philip Parkinson as CFO (then CEO, in 2007)	ORGN	[5 years]
2003 .10	Nomination : Reinhard Koenig [M.D.], as Vice President Clinical & Regulatory Affairs of Nautilus Biotech USA	ORGN	[3 years]
2000 .08	1st round-financing : 0.9 M€, by undisclosed investors	RFINA	[0 year]
2000 .01	Company founded by Dr Manuel Vega (CEO) et Paul Martin	ORGF	[0 year]

Actualisation / Updating: 11-Jan-2009

* NEURO3D *

2000 - Alsace
Mulhouse
www.neuro3d.com

Discovery, Drugs
(also, Contract, Research)
Key words: CNS, Psychiatry, Schizophrenia, Ocaperidone
Mission: to develop innovative treatments for psychiatric disorders such as schizophrenia, depression or anxiety
Clients: Prescribers
contact@neuro3d.com

Identity

TYPE/MANAGEMENT/INVESTORS	FINANCES/STATUS
Start-up \| Managing Dir.-CEO: Woler (Charles) Sc.Dir.-CSO: Fin.Dir.-CFO: Coste (Julien) BusDev: Financers (Hist.): Sofinnova Partners, Apax Partners	Turnover (M€) : 1.0 (2004) Total funding (M€) : 70.0 Last funding (M€) : 31.5 Focus : Multiple Position : Clinical Company confirm : n.a.

History

DATE	MILESTONE	TYPE	TIME
2007 .03	Liquidation and divestiture of R&D assets to Evotec (Germany)	INFO	[6 years]
2005 .05	Clinical trial (phase III) for key lead compound, ocaperidone, licensed to J&J (beginning)	CLIN	[4 years]
2004 .12	4th round-financing : 31.5 M€, by previous shareholders	RFIND	[4 years]
2003 .09	3rd round-financing : 10.0 M€, by previous shareholders	RFINC	[3 years]
2003 .05	Acquisition of Neurofit (France), a biotech CRO	ACQ+	[2 years]
2002 .09	2nd round-financing : 20.0 M€, led by HealthCap, with Techno Venture Management and previous shareholders	RFINB	[2 years]
2002 .03	Licensing-out of Ocaperidone to Janssen (J&J)	LICOUT	[1 year]
2000 .11	1st round-financing : 7.6 M€, by founder V.C., Apax Partners	RFINA	[0 year]
2000 .09	Company founded by Sofinnova, Charles Woler (CEO), Jean-Jacques Bourguignon, Jean-Paul Macher	ORGF	[0 year]

Actualisation / Updating: 12-Mai-2008

* NEUROTECH *

1998 -
www.neurotech.fr

Discovery, Drugs
Key words: Retinatis, CNTF, Encapsulated Cell Technology
Mission: to develop sight-saving therapeutics for chronic retinal diseases
Clients: Prescribers
t.shepherd@neurotech.fr

Identity

TYPE/MANAGEMENT/INVESTORS	FINANCES/STATUS
Personal venture \| Managing Dir.-CEO: Shepherd (Tom) Sc.Dir.-CSO: Fin.Dir.-CFO: BusDev: Financers (Hist.):	Turnover (M€) : Total funding (M€) : n.a. Last funding (M€) : n.a. Focus : Ophthalmo Position : Clinical Company confirm : n.a.

History

DATE	MILESTONE	TYPE	TIME
2006 .06	Company move from Paris to Delaware (USA), as the legal domicile, with change in nationality and website as www.neurotechusa.com	ORGL	[8 years]
2003 .11	4th round-financing : 12.0 M€, led by Apax Partners and Merlin Biosciences, with previous shareholders (3i Plc, GIMV, West LB, Atlas Venture and Ergo Equity)	RFIND	[5 years]
2002 .01	Licensing-in agreement of CNTF with Amgen in all ophthalmology indications	LICIN	[4 years]
2001 .05	3rd round-financing : 35.0 M€, led by Apax Partners and Merlin Biosciences with Westdeutsche Landesbank Girozentrale, ABN Amro, Rotschild, AGF Innovation, and previous shareholders (3I Plc, GIMV, Atlas Venture, CDC Innovation, Sofinnova, Sudinnova, Banque de Vizille, IMH)	RFINC	[3 years]
2000 .00	Set-up of US subsidiary in Lincoln	ORGC	[1 year]
1998 .10	Company founded by unknown entrepreneurs	ORGF	[0 year]

Actualisation / Updating: 12-Mai-2008

* NOVEXEL *

2004 - IDF
Romainville
(near Paris)
www.novexel.com

Discovery, Drugs
Key words: Anti-infectives, Anti-fungals
Mission: to develop novel antibacterials designed to overcome the significant global problem of bacterial resistance
Clients: Prescribers
info@novexel.com

Age: . AGE() . year(s)

Identity

TYPE/MANAGEMENT/INVESTORS

FINANCES/STATUS

Spin-off |
Managing Dir.-CEO: Buchanan (Iain) [born 1952, ex-Vertex, J&J, Biogen]
Sc.Dir.-CSO: Coleman (Kenneth) [Ph.D. microbiology, ex-AstraZeneca, SmithKline Beecham]
Fin.Dir.-CFO: Waldron (Gordon) [B.A. political science, ex-Syntem, Texas Instruments, Spie Batignolles]
BusDev: Mangasarian (Aram) [Ph.D. biology, MBA, ex-ExonHit Therapeutics]
Financers (Hist.): Sanofi-Aventis, Atlas Venture, Sofinnova, 3i, Abingworth, Novo

Turnover (M€) : 8.5 (2008)
Total funding (M€) : 90.0
Last funding (M€) : 50.0
Focus : Infections
Position : Clinical
Company confirm : neutral

History

DATE	MILESTONE	TYPE	TIME
2009 .12	Acquisition by AstraZeneca (UK) for at least US$ 430 Millions	ACQ-	[5 years]
2008 .11	Clinical trial (phase II) for combined NXL104/ceftazidime in Hospital Patients with complicated Urinary Tract Infections (beginning)	CLIN	[4 years]
2008 .04	Licensing-out of NXL 104, a beta-lactamase inhibitor, to Forest (USA), with € 75 Millions upfront payment	LICOUT	[3 years]
2008 .01	Set-up of US subsidiary in Pennsylvania	ORGC	[3 years]
2007 .01	2nd round-financing : 50.0 M€, led by Edmond de Rothschild I.P., with Goldman Sachs, NeoMed, NIF SMBC, and previous shareholders	RFINB	[2 years]
2006 .12	Licensing-in of Aminocandin from Indevus Biotech (USA)	LICIN	[2 years]
2005 .10	Clinical trial (phase I) for NXL 103 (beginning)	CLIN	[1 year]
2004 .12	1st round-financing : 40.0 M€, led by Atlas Venture, with Sofinnova, 3i, Abingworth, Novo	RFINA	[0 year]
2004 .12	Company founded by Dominique Le Beller and others, as a spin-off from Sanofi-Aventis [ex-Aventis Pharma]	ORGF	[0 year]

Actualisation / Updating: 04-Janv-2010

* OPI *

1999 - Rhône-Alpes
Lyon
www.orphan-opi.com

Discovery, Drugs
Key words: Orphan diseases, Hematology, Cancer, Transplants, Kidrolase, Erwinase
Mission: to discover and develop new treatment for orphan diseases
Clients: Pharmaceutical industry
opi@orphan-opi.com

Identity

TYPE/MANAGEMENT/INVESTORS	FINANCES/STATUS
Personal venture \| Managing Dir.-CEO: Alberici (Gilles) [founder, Pharm.D., Ph.D. immunotoxicology, ex-Mérieux, IMTIX-Sangstat] Sc.Dir.-CSO: Fin.Dir.-CFO: BusDev: Financers (Hist.): founder, Biomérieux, Sofimac, CDC-PME, Innoveris, SPEF, Siparex	Turnover (M€) : Total funding (M€) : 13.0 Last funding (M€) : 6.4 Focus : Multiple Position : Preclin Company confirm : n.a.

History

DATE	MILESTONE	TYPE	TIME
2007 .03	Acquisition by Eusa Pharma (USA)	ACQ-	[8 years]
2004 .04	3rd round-financing : 6.4 M€, led by SPEF and Siparex, with previous shareholders	RFINC	[5 years]
2003 .05	Acquisition of Diaclone (France)	ACQ+	[4 years]
2003 .00	2nd round-financing : 4.5 M€, by Sofimac, CDC-PME, Innoveris	RFINB	[3 years]
2001 .00	1st round-financing : 1.1 M€, by previous shareholders	RFINA	[1 year]
1999 .01	Company founded by Gilles Alberici [ex-Imtix, CEO], as 'Orphan Pharma International'	ORGF	[0 year]

Actualisation / Updating: 12-Mai-2008

* SHIGAMEDIX *

2005 - IDF
Paris
www.shigamedix.com

Discovery, Immunology
Key words: Antigen vectorization, Vaccines, Cancer, Infectious diseases, STxB Platform
Mission: to develop new vaccines based on antigen vectorization STxB proprietary technology designed to specifically target the dendritic cells
Clients: Prescribers
info@shigamedix.com

Identity

TYPE/MANAGEMENT/INVESTORS	FINANCES/STATUS
Spin-off \| Managing Dir.-CEO: Zacharie (Jean-Marie) [born 1941, HEC, Insead (MBA), ex-MSD] Sc.Dir.-CSO: Fin.Dir.-CFO: BusDev: Financers (Hist.): privately owned (registered capital 2006 = 0.04 M€)	Turnover (M€) : 0.036 (2007), 0.13 (2006) Total funding (M€) : n.a. Last funding (M€) : n.a. Focus : Vaccines Position : Preclin Company confirm : none

History

DATE	MILESTONE	TYPE	TIME
2009 .06	Company liquidation	INFO	[3 years]
2007 .11	Partnering research agreement with GSK Biologicals on vaccines	R&D	[2 years]
2006 .10	Nomination : Jean-Marie Zacharie, as President and CEO	ORGN	[1 year]
2005 .08	Company founded by Ludger Johannes [Ph.D.] from Curie Institute/CNRS and Eric Tartour [M.D./Ph.D.]	ORGF	[0 year]

Actualisation / Updating: 31-Oct-2008

* SYNT:EM *

1995 - Méditerranée
Nîmes
www.syntem.com

Discovery, Drugs
(also, Delivery, Drugs)
Key words: CNS, Brain barrier
Mission: to develop new drugs as well as to deliver compounds to the brain or other intracellular targets, based on proprietary Pep:trans and Acti:map technology platforms, in the field of CNS diseases
Clients: Prescribers
syntem@syntem.com

Identity

TYPE/MANAGEMENT/INVESTORS	FINANCES/STATUS
Personal venture \| Managing Dir.-CEO: Kaczorek (Michel) Sc.Dir.-CSO: Fin.Dir.-CFO: Waldron (Gordon) BusDev: Financers (Hist.): Apax Partners, Banexi Ventures, 3i, BankInvest, Lombart-Odier	Turnover (M€) : Total funding (M€) : 32.0 Last funding (M€) : n.a. Focus : CNS Position : Clinical Company confirm : n.a.

History

DATE	MILESTONE	TYPE	TIME
2006 .01	Acquisition by CLL Pharma (France), a development stage drug delivery pharmaceutical company, in shares	ACQ-	[11 years]
2004 .11	Acquisition (failed) by Sonus (USA), for 30 MUS$ in shares	ACQ-	[9 years]
1995 .00	Company founded by Michel Kaczorek (CEO), Caroline Roussel	ORGF	[0 year]

Actualisation / Updating: 12-Mai-2008

* THERAPTOSIS *

2001 - IDF
Romainville
(near Paris)
www.theraptosis.com

Discovery, Drugs
Key words: Apoptosis control, Cancer, Neuro-degenerative diseases, CytoTrust, MitoTrust
Mission: to design and develop drugs acting on key apoptosis regulators to fight diseases associated with lack or excess of apoptosis including cancer and neurodegenerative diseases
Clients: Pharmaceutical industry (own development up to clinical trials)
info@theraptosis.com

Age: . AGE() . year(s)

Identity

TYPE/MANAGEMENT/INVESTORS	FINANCES/STATUS
Spin-off \| Managing Dir.-CEO: Chesnoy (Olivier) [born 1958, M.D., ex-Fournier] Sc.Dir.-CSO: Jacotot (Etienne) [Ph.D., ex-Theraptosis (CEO)] Fin.Dir.-CFO: Boussard (Jean-François) [Ph.D.] BusDev: Financers (Hist.): Auriga Partners, EdRIP, SPEF, CDC, Blue Medical, Anvar	Turnover (M€) : 0.07 (2006) Total funding (M€) : 16.7 Last funding (M€) : 8.4 Focus : Cancers Position : Preclin Company confirm : none

History

DATE	MILESTONE	TYPE	TIME
2008 .12	Company liquidation (board of directors based decision)	INFO	[7 years]
2007 .09	Nomination : Olivier Chesnoy [M.D.] as CEO	ORGN	[6 years]
2007 .02	Company move to the Biocitech Park at Romainville (Paris North)	ORGL	[5 years]
2006 .12	2nd round-financing : 8.4 M€, led by Auriga Partners, with Blue Medical, Seventure, Edmond de Rothschild (EdRIP), CDC entreprises (FCJE)	RFINB	[5 years]
2006 .10	Registration : orphan drug designation by EMEA for a treatment of neonatal brain damage	MKTG	[5 years]
2002 .07	1st round-financing : 2.5 M€, by undisclosed investors	RFINA	[1 year]
2001 .03	Company founded by Léna Edelman and Etienne Jacotot, as a spin-off from Institut Pasteur, Paris	ORGF	[0 year]

Actualisation / Updating: 13-Nov-2009

* TRANSAT *

2002 - Rhône-Alpes
Saint-Priest
(near Lyon)
www.biotransat.com

Design, Drugs
(also Contract, Research)
Key words: Target delivery, Viral vectors, Functional genomics, Plasmid developments, Cellular models, Molecule libraries, RNA interference
Mission: to provide taylored cellular models and gene expression studies in functional genomics for third parties
Clients: Pharmaceutical industry, Biotech, Academic labs
transat@transatbiotechnology.com

Identity

TYPE/MANAGEMENT/INVESTORS	FINANCES/STATUS
Personal venture \| Managing Dir.-CEO: Chappuis (Sophie) [Ph.D., EM Lyon, ex-CNRS] Sc.Dir.-CSO: Fin.Dir.-CFO: BusDev: Financers (Hist.): Evolem, Oseo, Région Rhône-Alpes, privately owned	Turnover (M€) : 0.5 (2006) Total funding (M€) : 1.2 Last funding (M€) : 1.2 Focus : Genome Position : Preclin Company confirm : n.a.

History

DATE	MILESTONE	TYPE	TIME
2008 .03	Company liquidation	INFO	[5 years]
2006 .01	Seed financing : 1.2 M€, by Evolem, Oseo, Région Rhône-Alpes, and Philippe Desmarescaux (born 1938), as business angel	SFIN	[3 years]
2002 .12	Company founded by Sophie Chappuis and Marc Billaud (CNRS)	ORGF	[0 year]

Actualisation / Updating: 12-Mai-2008

* VALIGEN *

1996 - IDF
Courbevoie (near Paris)
www.valigen.com

Discovery, Drugs
Key words: Genomics, Chimeraplasty
Mission: to research in therapeutic target identification and validation using the tools of functional genomics and gene expression analysis, for treatments of cardio-vascular and metabolic conditions, and some cancers
Clients: Pharmaceutical industry, Agro industry
webmaster@valigen.com

Identity

TYPE/MANAGEMENT/INVESTORS	FINANCES/STATUS
Start-up \| Managing Dir.-CEO: Tharaud (Cécile) [Polytechnique, Ph.D., MBA, ex-Glaxo, SB] Sc.Dir.-CSO: Fin.Dir.-CFO: BusDev: Financers (Hist.):	Turnover (M€) : 0.18 (2001) Total funding (M€) : 30.0 Last funding (M€) : n.a. Focus : Multiple Position : Preclin Company confirm : n.a.

History

DATE	MILESTONE	TYPE	TIME
2002 .05	Company liquidation	INFO	[5 years]
2001 .05	Nomination : Cécile Tharaud, as CEO	ORGN	[4 years]
2000 .02	Acquisition of Kimeragen (USA), by merger	ACQ+	[3 years]
1997 .02	Acquisition of Infogen (Germany)	ACQ+	[0 year]
1996 .12	Company founded by Jean-Louis Pourny, from the merger of Valigène (France) and Kimeragen (USA)	ORGF	[0 year]

Actualisation / Updating: 12-Mai-2008

Actualisation / Updating: Feb 08 2010

Pharmaclient est le site-conseil de la Valorisation Client en Pharma...
Pour toute Mission, Inscription à la Pharmagalerie, Insertion dans la base Biotech, ou Question: CONTACT
Pour retourner à la page d'accueil Biotech: BIENVENUE !

Haut de page :

Pharmaclient, le site de la valorisation client en Pharma, est la vitrine des activités de conseil de Jean Huber: Stratégie, Communication, Relation Client en Pharma.

BIOTECH FRANCE MEMORIES

ONCE FRENCH BIOTECHS, TODAY ?... HATS-OFF TO VALOROUS TEAMS !

* ADIATEC *

Identity

History

* APTANOMICS *

Identity

History

* BIONEXIS PHARMACEUTICALS *

Identity

History

* BIONISIS *

Identity

History

* CAREX *

Identity

History

* CELOGOS *

Identity

History

* CELLPEP *

Identity

History

* DIATOS *

Identity

History

* DRUGABUSE SCIENCES *

Identity

History

* ENDOCELLS *

Identity

History

* FOVEA PHARMACEUTICALS *

Identity

History

* GÉNOPOÏETIC *

Identity

History

* GENSET *

Identity

History

* HEMOSYSTEM *

Identity

History

* IDM PHARMA *

Identity

History

* IVAGEN *

Identity

History

* MERISTEM THERAPEUTICS *

Identity

History

* NAUTILUS BIOTECH *

Identity

History

* NEURO3D *

Identity

History

* NEUROTECH *

Identity

History

* NOVEXEL *

Identity

History

* OPI *

Identity

History

* SHIGAMEDIX *

Identity

History

* SYNT:EM *

Identity

History

* THERAPTOSIS *

Identity

History

* TRANSAT *

Identity

History

BIOTECH FRANCE
MEMORIES